VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Tisagenlecleucel in pediatric R/R B-cell ALL

Andre Baruchel, MD, PhD, of Hôpital Robert Debre, Paris, France, discusses tisagenlecleucel for pediatric/young adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) as evaluated in the B2001X study (NCT03123939) focusing on prior exposure to blinatumomab and inotuzumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter